134 related articles for article (PubMed ID: 25180747)
1. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.
Al-Naamani N; Roberts KE; Hill NS; Preston IR
Chest; 2014 Sep; 146(3):e81-e83. PubMed ID: 25180747
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
3. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
4. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
5. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
8. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
Querejeta Roca G; Campbell P; Claggett B; Vazir A; Quinn D; Solomon SD; Shah AM
Eur J Heart Fail; 2015 Jan; 17(1):63-73. PubMed ID: 25367310
[TBL] [Abstract][Full Text] [Related]
9. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
10. [Experience with imatinib to treat pulmonary arterial hypertension].
García Hernández FJ; Castillo Palma MJ; González León R; Garrido Rasco R; Ocaña Medina C; Sánchez Román J
Arch Bronconeumol; 2008 Dec; 44(12):689-91. PubMed ID: 19091239
[TBL] [Abstract][Full Text] [Related]
11. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Ciuclan L; Hussey MJ; Burton V; Good R; Duggan N; Beach S; Jones P; Fox R; Clay I; Bonneau O; Konstantinova I; Pearce A; Rowlands DJ; Jarai G; Westwick J; MacLean MR; Thomas M
Am J Respir Crit Care Med; 2013 Jan; 187(1):78-89. PubMed ID: 23087024
[TBL] [Abstract][Full Text] [Related]
12. A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
Ormiston ML; Deng Y; Rundle N; Bendjelloul F; Tsoporis JN; Parker TG; Stewart DJ; Courtman DW
Am J Pathol; 2013 May; 182(5):1541-51. PubMed ID: 23518411
[TBL] [Abstract][Full Text] [Related]
13. [Imatinib for pulmonary arterial hypertension].
Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
[No Abstract] [Full Text] [Related]
14. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.
Minatsuki S; Miura I; Yao A; Abe H; Muraoka H; Tanaka M; Imamura T; Inaba T; Maki H; Hatano M; Kinugawa K; Yao T; Fukayama M; Nagai R; Komuro I
Int Heart J; 2015; 56(2):245-8. PubMed ID: 25740390
[TBL] [Abstract][Full Text] [Related]
15. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.
Ghofrani HA; Morrell NW; Hoeper MM; Olschewski H; Peacock AJ; Barst RJ; Shapiro S; Golpon H; Toshner M; Grimminger F; Pascoe S
Am J Respir Crit Care Med; 2010 Nov; 182(9):1171-7. PubMed ID: 20581169
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Grinnan DC; Fairman P; Pinson J
Chest; 2007 Dec; 132(6):2057-8; author reply 2058. PubMed ID: 18079249
[No Abstract] [Full Text] [Related]
17. Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Arita S; Arita N; Hikasa Y
Can Vet J; 2013 Mar; 54(3):255-61. PubMed ID: 23997262
[TBL] [Abstract][Full Text] [Related]
18. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Toba M; Alzoubi A; O'Neill K; Abe K; Urakami T; Komatsu M; Alvarez D; Järvinen TA; Mann D; Ruoslahti E; McMurtry IF; Oka M
Am J Pathol; 2014 Feb; 184(2):369-75. PubMed ID: 24401613
[TBL] [Abstract][Full Text] [Related]
19. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Godinas L; Guignabert C; Seferian A; Perros F; Bergot E; Sibille Y; Humbert M; Montani D
Semin Respir Crit Care Med; 2013 Oct; 34(5):714-24. PubMed ID: 24037637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]